July/August 2025 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Movers of the Month
iOnctura, a clinical-stage biopharmaceutical company focused on neglected and hard-to-treat cancers, has appointed Steven Sciuto as Chief Financial Officer and Michelle Tsai as Chief Operating Officer.
The appointments support iOnctura’s continued growth and follow the advancement of several phase 2 studies for its lead programme, roginolisib.
CEO and co-founder Catherine Pickering said: “As we enter the next phase of our strategy, every new leader has been carefully chosen for their expertise, vision and ability to drive transformative growth – and Steve and Michelle join us to do just that.”
Steven brings over 15 years of corporate finance and capital markets expertise in life sciences, having raised more than $400 million and led complex financial operations. He was most recently Vice President of Finance at Neurogene Inc.
He commented: “With a strong foundation already in place, and an unrelenting mission to combat rare and hard-to-treat cancers, I look forward to working with the talented team at iOnctura to drive financial and strategic initiatives.”
Michelle is a global commercial leader with more than 20 years’ experience in oncology and specialty pharmaceuticals.
She has led worldwide commercial launches for blockbuster oncology brands at Novartis, and brings deep expertise in portfolio strategy, life cycle planning and cross-functional leadership from preclinical through phase 3.
She said: “With a strong commitment to advancing novel treatments and delivering potentially life-changing therapies to patients, I look forward to working alongside the team to shape the strategy and ensure iOnctura’s innovative pipeline reaches those who need them most.”
Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board.
This move strengthens the Board as Clinigen advances its strategic transformation and expands its role across the full pharmaceutical life cycle.
Paul brings nearly 30 years of global biopharma leadership experience, having held senior roles at Gilead Sciences, GlaxoSmithKline and SmithKline Beecham. At Gilead, he oversaw global commercial operations and $30 billion in annual revenue.
His experience spans North America, Europe and Asia, with a strong track record in commercial strategy and leadership.
In addition to his executive roles, Paul holds numerous board and advisory positions. He is currently Chair of Memo Therapeutics AG and Kyowa Kirin International PLC, and Board Director at Immatics NV. He also advises several healthcare investors and life sciences companies, and mentors executives via GLG Institute and Pioneering Collective.
Paul’s appointment comes at a pivotal time for Clinigen. His experience in launching market-leading products, scaling global operations and forming strategic partnerships will support the company’s goal of becoming the world’s premier end-to-end pharmaceutical life cycle partner.
Jerome Charton, CEO at Clinigen, commented: “Paul Carter's appointment as Chair represents a significant milestone for Clinigen as we continue our strategic transformation. His visionary leadership and unparalleled commercial experience will be instrumental in executing our ambitious growth strategy.”
Veranova has appointed Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence.
Bringing over 20 years of industry experience, Elizabeth has held senior roles across pharmaceutical, life sciences and manufacturing sectors. She previously served as Vice President of Supply Chain, Procurement and Customer Service at QuVa Pharma.
Her earlier leadership positions include global supply chain and procurement roles at Recipharm, Catalent, Wave Life Sciences, Shire Pharmaceuticals and Lonza.
A certified Lean Six Sigma Master Black Belt, she is recognised for her strategic insight, transformative leadership and ability to build
high-performing teams that deliver measurable results.
Mike Riley, Chief Executive Officer of Veranova, said: “Elizabeth’s deep expertise and proven track record in supply chain and operational excellence will be instrumental in helping Veranova achieve greater consistency, efficiency and scalability across our global operations
Closed Loop Medicine (CLM) has appointed Kate Woolland as Chief Executive Officer. Previously serving as Chief Operating Officer, she will lead the company into a new phase focused on scaling its innovation platform through strategic partnerships and commercialisation of its intellectual property.
CLM has built a global IP portfolio with more than 60 filings across 16 patent families, covering platform and therapy-specific dosing technologies, including GLP-1 therapies and hypertension.
With clearances in the UK and US and ISO13485/ISO27001 certification, the company is well-positioned for expansion in the growing metabolic health sector. Its titration-based approach has demonstrated improved adherence above 90% in clinical settings.
Kate said: “Our precision dosing platform has reached a maturity that creates strategic value for pharmaceutical and health delivery partners. As we enter this new phase, we're focused on partnering with organisations that can leverage our technology at scale across multiple therapeutic areas.”
She brings deep commercial and operational experience to the role, having previously launched healthcare products at ieso Digital Health and built a multimillion-pound health transformation practice at PA Consulting.
Her focus will be on maximising the value of CLM’s platform through pharmaceutical partnerships, life cycle management and digital health integration, while also supporting differentiated generics.
Chair of the Board, Luba Greenwood, noted: “Kate’s appointment is well timed as we transition from product development to value realisation. Her commercial insight and strategic focus are exactly what’s needed for this next phase.”
Enhanced Genomics has appointed
Dr Dietrich Stephan as Chair of the Board of Directors.
In this role, Dietrich will guide strategic initiatives including the expansion of the company’s internal pipeline, initially focused on autoimmune diseases, and the formation of partnerships to accelerate drug discovery and clinical trial stratification.
A renowned genomics expert and biotech entrepreneur, Dr Stephan has held multiple C-level and board roles, leading over two dozen private and public biotech companies through scale-up, financing and acquisition.
He has also overseen high-throughput genomics programmes, including the neuroscience genomics consortium at the US National Institutes of Health and has helped uncover the genetic drivers of hundreds of diseases.
Dietrich commented: “Enhanced Genomics’ 3D single cell-type multi-omics platform is uniquely capable of translating massive disease-associated data into actionable biology. It offers game-changing potential to identify novel, genetically validated therapeutic targets for common diseases.”
Joanna Smart, Investor Director, BGF, reflected: “Multi-omics is the next frontier of the genomics revolution — and Enhanced is leading the way. Dietrich’s track record in high-throughput genomics and biotech leadership will be pivotal as the company enters its next growth phase.”
Enhanced Genomics’ proprietary 3D multi-omics platform connects disease-associated genetic variants to causative genes in specific cell types, enabling rapid identification of high-confidence therapeutic targets.
VectorY Therapeutics has appointed Jessica Atkinson as Chief Business Officer. In this newly created role, she will support the CEO and leadership team in shaping long-term commercial strategy and forging key partnerships.
Jessica brings over 20 years’ experience in business development and commercial strategy within biopharma. She has held leadership roles at ImmuneID, Glympse Bio and Foundation Medicine, where she drove corporate strategy and strategic partnerships.
She also spent seven years in the US commercial team at Merck & Co. Most recently, she advised multiple early-stage biotech companies through her consultancy, TwoStep Advisors.
CEO Jim Scibetta commented: “Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities.”
Jessica added: “VectorY’s pioneering approach to developing vectorised antibody therapeutics holds immense promise for patients with neurodegenerative diseases. I look forward to working with the team to grow our strategy and build transformative alliances that support our mission and long-term success.”
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.